ArticleTranslational cancer research2026
Kinase-based molecular subtyping and a prognostic risk model in colorectal cancer with functional validation of PLK4.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) exhibits marked molecular heterogeneity, yet prognostic tools centered specifically on protein kinases remain scarce. This study aimed to identify kinase-related molecular subtypes of CRC and to develop and validate a kinase-based prognostic risk model integrating clinical and immune features. Methods: Transcriptomic data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) were integrated to identify prognosis-related kinase genes. Unsupervised consensus clustering was used to define molecular subtypes, and differences in survival, immune infiltration, and immune checkpoint expression between subtypes were assessed. A nine-gene prognostic model was constructed using least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression and validated in an independent external cohort. Associations with the consensus molecular subtypes (CMS), tumor mutational burden (TMB), drug sensitivity, and immunotherapy response were analyzed. The expression of core genes was verified by quantitative real-time polymerase chain reaction (qRT-PCR) in CRC cell lines, and the function of Results: Consensus clustering revealed two distinct kinase-based subtypes with significantly different survival; the poorer-prognosis subtype overlapped predominantly with CMS4 and showed altered immune infiltration. The nine-gene risk model provided reproducible prognostic stratification, remained an independent predictor of survival after adjustment for tumor-node-metastasis (TNM) stage, and was validated in the external validation cohort. Compared with high-risk patients, low-risk patients showed higher TMB and greater predicted responsiveness to immunotherapy and selected chemotherapeutic agents. qRT-PCR confirmed that nine core genes exhibited expression trends consistent with the bioinformatics predictions, and Conclusions: This kinase-based subtyping and prognostic model offers a complementary tool for risk stratification and individualized treatment decisions in CRC. Further multi-omics and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.